Feasibility of multiomics tumor profiling for guiding treatment of melanoma

There is limited evidence supporting the feasibility of using omics and functional technologies to inform treatment decisions. Here we present results from a cohort of 116 melanoma patients in the prospective, multicentric observational Tumor Profiler (TuPro) precision oncology project. Nine independent technologies, mostly at single-cell level, were used to analyze 126 patient samples, generating up to 500 Gb of data per sample (40,000 potential markers) within 4 weeks. Among established and experimental markers, the molecular tumor board selected 54 to inform its treatment recommendations. In 75% of cases, TuPro-based data were judged to be useful in informing recommendations. Patients received either standard of care (SOC) treatments or highly individualized, polybiomarker-driven treatments (beyond SOC). The objective response rate in difficult-to-treat palliative, beyond SOC patients (n = 37) was 38%, with a disease control rate of 54%. Progression-free survival of patients with TuPro-informed therapy decisions was 6.04 months, (95% confidence interval, 3.75–12.06) and 5.35 months (95% confidence interval, 2.89–12.06) in ≥third therapy lines. The proof-of-concept TuPro project demonstrated the feasibility and relevance of omics-based tumor profiling to support data-guided clinical decision-making.

Keywords

Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Feasibility Studies, Female, Genomics, Humans, Male, Melanoma, Middle Aged, Multiomics, Precision Medicine, Progression-Free Survival, Prospective Studies, Skin Neoplasms

Subject (DDC)

610 - Medizin und Gesundheit

Project

Event

Exhibition start date

Exhibition end date

Conference start date

Conference end date

Date of the last check

ISBN

ISSN

1078-8956
1546-170X

Language

English

Created during FHNW affiliation

Yes

Strategic action fields FHNW

Publication status

Published

Review

Peer review of the complete publication

Open access category

Hybrid

License

Citation

Miglino, N., Toussaint, N. C., Ring, A., Bonilla, X., Tusup, M., Gosztonyi, B., Mehra, T., Gut, G., Jacob, F., Chevrier, S., Lehmann, K.-V., Casanova, R., Jacobs, A., Sivapatham, S., Boos, L., Rahimzadeh, P., Schuerch, M., Sobottka, B., Chicherova, N., et al. (2025). Feasibility of multiomics tumor profiling for guiding treatment of melanoma. Nature Medicine, 31, 2430–2441. https://doi.org/10.1038/s41591-025-03715-6

Full item page